Home > Compound List > Product Information
KR-32568_Molecular_structure_CAS_852146-73-7)
Click picture or here to close

KR-32568

Catalog No. K4389 Name Sigma Aldrich
CAS Number 852146-73-7 Website http://www.sigmaaldrich.com
M. F. C13H12FN3O2 Telephone 1-800-521-8956
M. W. 261.2516832 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 154026

SYNONYMS

IUPAC name
N-carbamimidoyl-5-(5-fluoro-2-methylphenyl)furan-2-carboxamide
IUPAC Traditional name
N-carbamimidoyl-5-(5-fluoro-2-methylphenyl)furan-2-carboxamide
Synonyms
[5-(2-Methyl-5-fluorophenyl)furan-2-ylcarbonyl]guanidine

DATABASE IDS

CAS Number 852146-73-7
PubChem SID 24724522
MDL Number MFCD08705324

PROPERTIES

Empirical Formula (Hill Notation) C13H12FN3O2
Purity ≥98% (HPLC)
Gene Information human ... SLC9A1(6548)
Apperance white solid
Solubility DMSO: ~10 mg/mL
GHS Pictograms GHS07
GHS Signal Word Warning
GHS Hazard statements H302-H315-H319-H335
European Hazard Symbols Harmful Harmful (Xn)
MSDS Link Download
Personal Protective Equipment Eyeshields, Faceshields, full-face respirator (US), Gloves, multi-purpose combination respirator cartridge (US), type ABEK (EN14387) respirator filter
GHS Precautionary statements P261-P305 + P351 + P338
Risk Statements 22-36/37/38
Safety Statements 26-36
Storage Temperature 2-8°C
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
Sodium/hydrogen exchanger-1 (NHE-1) inhibitor; IC50 = 0.23 μM; inhibited NHE-1-mediated rabbit platelet swelling; in anesthetized rats, reduced infarct size from 67% (control) to 43% (at 0.1 mg/kg) and 24% (at 1.0 mg/kg); reduced number of ventricular premature beats from 530 to 266 (at 0.1 mg/kg) and 115 (at 1.0 mg/kg); reduced ventricular fibrillation incidence from 17 to 8 (0.1 mg/kg) and 0 (1.0 mg/kg); implications for research and treatment of myocardial ischemic diseases.
Description (简体中文)
Biochem/physiol Actions
Sodium/hydrogen exchanger-1 (NHE-1) inhibitor; IC50 = 0.23 μM; inhibited NHE-1-mediated rabbit platelet swelling; in anesthetized rats, reduced infarct size from 67% (control) to 43% (at 0.1 mg/kg) and 24% (at 1.0 mg/kg); reduced number of ventricular premature beats from 530 to 266 (at 0.1 mg/kg) and 115 (at 1.0 mg/kg); reduced ventricular fibrillation incidence from 17 to 8 (0.1 mg/kg) and 0 (1.0 mg/kg); implications for research and treatment of myocardial ischemic diseases.

REFERENCES